OTCPicks.com’s Daily Small Cap and Microcap Newsletter presents a range of the hottest small cap stocks on trading on the OTC and OTCBB markets. In addition to our Newsletters, OTCPicks.com is quickly becoming the premier community destination for small cap and microcap traders to meet up and discuss their top stock picks. Visit http://www.otcpicks.com/ today to join this growing community.
Our Stocks to Watch today include BioSolar Inc. (OTCBB: BSRC), Lantis Laser Inc. (OTC: LLSR), Accentia Biopharmaceuticals Inc. (NASDAQ: ABPI), Biovest International Inc. (OTCBB: BVTI), Enzyme Environmental Solutions Inc. (OTC: EESO), Cyberhand Technologies International Inc. (OTC: CYHA)
For the complete newsletter please visit: http://www.otcpicks.com/daily-market-movers/index.php
For more in-depth coverage of small cap stocks visit http://www.otcpicks.com/
BIOSOLAR INCORPORATED (OTC: BSRC)
"Up 5.56% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BSRC.php
Company Profile: http://www.otcpicks.com/biosolar/biosolar-2.htm
BioSolar, Inc. engages in the research and development of bioplastic materials from renewable plant sources for use in photovoltaic solar cells. The company develops bio-based plastics components that meet the thermal and durability requirements of solar cell manufacturing processes for conventional crystalline cell designs, as well as thin film photovoltage devices in an effort to capitalize on cost advantages to current petroleum based solar cell components. Its bioplastic materials can be also used directly in conventional manufacturing systems, such as injection molding and thin-film roll-to-roll, to create superstrate layer, substrate layer, and backsheet, as well as module and panel components. The company was founded in April 2006. It was formerly known as BioSolar Labs, Inc. and changed its name to BioSolar, Inc. in June 2006. BioSolar, Inc. is headquartered in Santa Clarita, California.
LANTIS LASER INCORPORATED (OTC: LLSR)
"Up 4.35% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/LLSR.php
Company Profile: http://www.otcpicks.com/lantis-laser/lantis-laser-2.htm
Lantis Laser was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System™ in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); LightLab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser, visit http://www.lantislaser.com/.
ACCENTIA BIOPHARMACEUTICALS (NASDAQ: ABPI)
"Up 33.94% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BPAX.php
Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology. It operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products. Its products, which are under Phase III clinical trials, include SinuNase for the treatment of chronic rhinosinusitis; BiovaxID, a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma; and Revimmune for the treatment of multiple sclerosis, an autoimmune disease that affects the central nervous system, and various autoimmune diseases, including systemic lupus, myasthenia gravis, and aplastic anemia. This segment also provides various consulting services relating to biopharmaceutical product development; and engages in the production of custom biologic products and cell culture instruments and systems for biopharmaceutical and biotechnology companies, medical schools, universities, hospitals, and research institutions. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by third-party development partners. Its products comprise Respi-TANN, a prescription antitussive decongestant for temporary relief of cough and nasal congestion; SinuTest, a test used in connection with the diagnosis of chronic sinusitis; and Zinotic, a treatment of superficial infections of the external ear. This segment's products under development include AllerNase, a formulated suspension of an intranasal topical steroid indicated for the treatment of allergic and non-allergic rhinitis; and Emezine, a product for control of nausea and vomiting. The company was founded in 2002 and is headquartered in Tampa, Florida.
BIOVEST INTERNATIONAL INCORPORATED (OTCBB: BVTI)
"Up 24.39% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BVTI.php
Biovest International, Inc., a biotechnology company, develops therapeutic anti-cancer vaccine for the treatment of low-grade Follicular Lymphoma in the United States. It develops BiovaxID, a Phase III clinical trial product, which is an injectable patient-specific vaccine to treat the follicular form of non-Hodgkin's lymphoma. The company develops, manufactures, and markets cell culture systems, equipment, and consumable parts to pharmaceutical, diagnostic, and biotechnology companies, as well as to research institutions worldwide. Biovest International also produces mammalian and insect cells, monoclonal antibodies, recombinant and secreted proteins, and other cell culture products using hollow fiber perfusion. It is also developing an automated cell culture instrument, AutovaxID that enables production of personalized cell-based treatments. In addition, the company sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. Further, Biovest International engages in the production and contract manufacture of biologic drugs and cell production for research institutions. The company has a cooperative research and development agreement with the National Cancer Institute for the development and commercialization of patient-specific vaccines for the treatment of non-Hodgkin's low-grade follicular lymphoma. Its customers include biopharmaceutical and biotech companies, medical schools, universities, research facilities, hospitals, and public and private laboratories. The company was incorporated in 1981 as Endotronics, Inc. and changed its name to Cellex Biosciences, Inc. in 1993. Further, it changed its name to Biovest International, Inc. in 2001. The company is based in Worcester, Massachusetts. Biovest International, Inc. is a subsidiary of Accentia Biopharmaceuticals, Inc.
ENZYME ENVIRONMENTAL SOLUTIONS (OTC: EESO)
"Up 12.50% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EESO.php
Enzyme Environmental Solutions is a U.S.-based manufacturer of industrial and agricultural enzyme products. All manufacturing, testing, and formulating are conducted in its manufacturing plant, located in Fort Wayne, Indiana. EESO strives to become a leader in ecological friendly or “green products” targeting the industrial and agricultural markets. It is the company's goal to have the best performing products on the market in each industry. Developing a growing and satisfied customer base is its number one marketing strategy.
About OTCPicks.com
OTCPicks.com is fast becoming the premier Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Research Reports authored by our financial writers. We publish our Daily Market Movers Digest Newsletter to opt-in investor members. OTCPicks.com presents the latest information for the discerning small cap and microcap investor. The site features informative articles on microcap investing, the top penny stock picks, and a wealth of small cap research on vertical markets. To feature a company on OTCPicks.com, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Disclosure: OTCPicks.com has been compensated seven thousand five hundred dollars by a non-controlling third party for UITK advertising and promotional services.
OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.
